Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

AOD-9604 Research Guide: HGH Fragment 176-191 Explained (2026)

Back to library
peptide

AOD-9604 Research Guide: HGH Fragment 176-191 Explained (2026)

16 min read

Last Updated: April 2026

AOD-9604 (CAS: 221231-10-3) is a synthetic 16-amino acid peptide derived from the C-terminal region of human growth hormone, specifically residues 176-191, with a stabilising tyrosine modification at the N-terminus. It was engineered to isolate the fat-metabolising properties of hGH without activating the growth hormone receptor, raising IGF-1 levels, or affecting glucose homeostasis. Preclinical research showed significant lipolytic and anti-lipogenic effects. Six human clinical trials enrolled over 900 participants. Development as an obesity drug was discontinued in 2007 after Phase IIb trials failed to meet efficacy endpoints. AOD-9604 remains actively studied as a research chemical for metabolic biology.

This guide covers what AOD-9604 is, how it differs from full-length hGH and HGH Fragment 176-191, its mechanism of action, the complete published research record, storage requirements for laboratory use, and UK legal status.

Key Takeaways

  • CAS number: 221231-10-3. Molecular formula: C78H123N23O23S2. Molecular weight: approximately 1,817 Da. Sequence: Tyr-hGH 177-191 (16 amino acids including the stabilising N-terminal tyrosine)
  • AOD-9604 does not activate the growth hormone receptor, does not raise IGF-1, and does not impair glucose tolerance – confirmed across six human clinical trials (Stier et al., 2013; PMID: 23761285)
  • Primary mechanism: beta-3 adrenergic receptor upregulation driving lipolysis in adipose tissue; secondary mechanism: inhibition of lipogenesis via acetyl-CoA carboxylase inhibition
  • Preclinical evidence is strong – significant fat reduction in obese rodent models, confirmed via genetic knockout study. Human efficacy data is weaker – Phase IIb trials did not demonstrate statistically significant weight loss at scale
  • Emerging secondary research area: intra-articular AOD-9604 enhanced cartilage regeneration in a rabbit osteoarthritis model (Kwon et al., 2015)
  • Legal in the UK as a research chemical for laboratory use. Not MHRA approved. Banned by WADA under S0 category

Compound Identity and Technical Specifications

Parameter Detail
Common name AOD-9604 / AOD9604 / Advanced Obesity Drug 9604
CAS number 221231-10-3
Molecular formula C78H123N23O23S2
Molecular weight ~1,817 Da
Sequence Tyr-hGH 177-191 (N-terminally tyrosine-modified fragment of hGH)
Developed by Metabolic Pharmaceuticals Ltd., Australia (Professor Frank Ng, Monash University, 1990s)
Development status Discontinued after Phase IIb (2007). Retained as research compound
UK legal status Research chemical – legal for laboratory use. Not MHRA approved
WADA status Banned – S0 category (non-approved substances)

AOD-9604 vs HGH Fragment 176-191: What’s the Difference?

These two terms are frequently used interchangeably online. They refer to closely related but chemically distinct compounds, and the distinction matters for research accuracy.

HGH Fragment 176-191 AOD-9604
Description Natural sequence of amino acids 176-191 at the C-terminal end of hGH Modified version: same sequence but with a tyrosine residue at the N-terminus
Amino acids 15 (residues 176-191) 16 (Tyr + residues 177-191)
Human trials None Six RCTs (900+ participants)
Practical difference Simpler structure; studied as the natural GH fragment Modified structure; more clinical data; more frequently cited in research literature

The tyrosine modification in AOD-9604 was engineered to improve stability and bioavailability compared to the native fragment. This modification is why AOD-9604 – not the raw fragment – was the version that progressed into formal clinical trials. For precise laboratory documentation, the distinction should be noted.

Why This Compound Matters for Metabolic Research

When Professor Frank Ng’s team at Monash University first synthesised AOD-9604 in the 1990s, they were trying to solve a specific problem. Full-length human growth hormone does promote fat loss – but it also causes insulin resistance, raises IGF-1, stimulates bone and organ growth, and carries significant side effect risk. The question was whether the fat-metabolising activity of hGH could be separated from everything else. AOD-9604 was the answer they built.

AOD-9604’s research value lies in a specific characteristic: it allows the study of lipolytic signalling pathways in adipose tissue without the confounding endocrine effects of full growth hormone therapy. When researchers want to understand how the beta-3 adrenergic receptor pathway drives fat breakdown, using full hGH introduces too many simultaneous variables. AOD-9604 isolates the metabolic subset of hGH activity.

This clean separation is the reason AOD-9604 retained research value even after its development as an obesity drug was terminated. The compound’s failure as a drug was an efficacy failure in humans – not a failure to demonstrate that the mechanism exists.

AOD-9604 for Laboratory Research

CAS 221231-10-3. Batch-specific COA, HPLC purity verification, mass spectrometry identity confirmation on every order.

Browse AOD-9604 →

Mechanism of Action

AOD-9604 operates through two established mechanisms in preclinical models, both centred on adipose tissue metabolism. Neither mechanism involves the growth hormone receptor, and neither produces the IGF-1 elevation or glucose disruption associated with full hGH.

Beta-3 Adrenergic Receptor Upregulation and Lipolysis

The primary mechanism identified in published research is upregulation of beta-3 adrenergic receptors (beta-3 ARs) on adipocytes. Beta-3 ARs are G protein-coupled receptors expressed predominantly in adipose tissue and brown fat. When activated, they trigger a signalling cascade increasing intracellular cyclic AMP (cAMP), which activates hormone-sensitive lipase (HSL) – the enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol. This process is lipolysis – which means AOD-9604 directly stimulates the breakdown of stored body fat at a cellular level.

The mechanistic evidence comes from a pivotal experiment published in Endocrinology in 2001 (Heffernan et al., PMID: 11713213). The study compared AOD-9604’s lipolytic effects in normal obese mice against beta-3 AR knockout mice – animals genetically engineered to lack the receptor. In normal mice, AOD-9604 significantly reduced body weight and fat mass. In the knockout mice, these effects were completely absent. This genetic pathway confirmation is more conclusive than most peptide mechanism studies, which typically only demonstrate downstream effects without genetic validation.

AOD-9604’s selectivity for beta-3 ARs over beta-1 and beta-2 adrenergic receptors prevents the cardiovascular side effects (tachycardia, tremor) associated with non-selective adrenergic stimulation – which means the fat metabolism signal is delivered without the cardiac noise that limits other adrenergic approaches.

Inhibition of Lipogenesis via Acetyl-CoA Carboxylase

The second documented mechanism is inhibition of lipogenesis – the creation of new fat from dietary substrates. Published research found that AOD-9604, like full hGH, inhibits acetyl-CoA carboxylase (ACC) in isolated rat adipose tissue (Ng et al., 1997, Molecular and Cellular Endocrinology). ACC is the rate-limiting enzyme in the synthesis of fatty acids from acetyl-CoA. When ACC is inhibited, the body’s capacity to create new fat stores is reduced – which means AOD-9604 works on both sides of the fat storage equation: stimulating breakdown through lipolysis while inhibiting new synthesis.

What AOD-9604 Does Not Do

Equally important as what it does is what it doesn’t do – and what differentiates it as a research tool from full hGH:

  • Does not activate the growth hormone receptor (GHR) – confirmed across multiple studies
  • Does not elevate IGF-1 levels – confirmed in all six human clinical trials
  • Does not impair insulin sensitivity or glucose tolerance – confirmed in Phase I and Phase IIa trials including intravenous administration at doses up to 400 mcg/kg
  • Does not stimulate muscle growth or linear bone growth – effects are confined to adipose tissue metabolism
  • No anti-AOD-9604 antibodies were detected in clinical trial participants (Stier et al., 2013) – no evidence of immunogenicity

Daniel had been studying adipocyte signalling for three years. He wanted a compound that would activate the beta-3 adrenergic pathway in isolated fat cell cultures without triggering the GH receptor or raising IGF-1 – because both would confound his downstream measurements. He’d used isoprenaline in earlier protocols but wanted something more selective. He came across the Heffernan et al. 2001 beta-3 AR knockout study and saw exactly the mechanistic specificity he needed. The compound’s failure as a weight loss drug was irrelevant to his research question. The mechanism was what mattered.

Key Published Research

Preclinical Studies: Animal Models

Heffernan et al. (2001) – Beta-3 AR Knockout Study | Endocrinology, 142(12):5182-5189 | PMID: 11713213

The most mechanistically important AOD-9604 study. Compared effects in normal obese mice versus beta-3 adrenergic receptor knockout mice. In normal mice, chronic AOD-9604 treatment significantly reduced body weight and fat mass, increased fat oxidation, and reduced adipose tissue mass. In beta-3 AR knockout mice, none of these effects were observed. Also demonstrated that AOD-9604 did not affect lean body mass, glucose tolerance, or IGF-1 levels in either model.

Heffernan et al. (2001) – Obese Mouse Model | Obesity Research, 9(5):341-347 | PMID: 11673763

Examined effects in ob/ob (genetically obese) mice and diet-induced obese mice. Chronic administration produced significant reductions in fat mass, increased fat oxidation measured by indirect calorimetry, and stimulated lipolysis in adipose tissue. Animals treated with AOD-9604 showed decreased average adipocyte cell size compared to controls – a histological confirmation of fat cell volume reduction, not merely weight change.

Heffernan et al. (2000) – Adipose Tissue Lipolysis and Lipogenesis | American Journal of Physiology – Endocrinology and Metabolism, 279(3):E501-507 | PMID: 10950816

Examined direct effects on isolated adipose tissue ex vivo. Found that AOD-9604 increased lipolysis and reduced lipogenesis in human adipose tissue samples as well as animal tissue – giving early confidence that the mechanisms observed in animal models would be relevant to human biology.

Human Clinical Trials

Six randomised, double-blind, placebo-controlled trials were completed by Metabolic Pharmaceuticals Ltd. between the late 1990s and 2007.

Stier et al. (2013) – Pooled Safety Analysis of Six Trials | Journal of Endocrinology and Metabolism, 3(1-2):7-15 | PMID: 23761285

The definitive AOD-9604 safety publication. Pooled analysis of all six clinical trials representing 900+ participants across Phase I through Phase IIb. Key findings: no significant elevation of IGF-1 at any dose or administration route (oral or intravenous); no impairment of glucose tolerance or insulin sensitivity; no detection of anti-AOD-9604 antibodies; adverse event profile indistinguishable from placebo across all six trials. Tolerability confirmed at oral doses up to 30 mg/day and intravenous doses up to 400 mcg/kg.

Phase IIb – METAOD005 (Primary Efficacy Trial)

300 obese adults (BMI ≥35), 12-week, multiple oral doses (1-30 mg/day). Primary endpoint: reduction in body weight. Results: 1 mg/day arm lost a mean of 2.6 kg vs 0.8 kg in placebo – statistically significant at that dose. Higher doses did not produce greater weight loss than placebo, and the effect size at all doses was considered insufficient for commercial development. Development was terminated after this trial.

Phase IIb – METAOD006 (24-week Extension Trial)

502 obese adults randomised to 0.25 mg, 0.5 mg, 1 mg daily oral or placebo for 24 weeks. Failed to replicate statistically significant weight loss advantage over placebo at any dose in the longer timeframe. This failure at extended duration was the final endpoint that led to development discontinuation in 2007.

The clinical trial picture is clear: AOD-9604 is safe and well-tolerated in humans, does not impair glucose or IGF-1, and showed a modest weight loss signal at low doses in one short-term trial that was not sustained or replicated at scale. As an anti-obesity drug, the efficacy case was not established. As a research tool for studying lipolytic pathways, the safety profile and selectivity remain relevant.

900+ Human Trial Participants. Full Safety Profile Documented.

AOD-9604 from Pure Grade Labs – HPLC purity verified, mass spectrometry identity confirmed, batch-specific COA. For in vitro laboratory research use.

Shop the Full Range →

Cartilage and Osteoarthritis Research

Kwon et al. (2015) – Intra-articular AOD-9604 in Rabbit OA Model | Annals of Clinical and Laboratory Science, 45(4):426-432

32 mature New Zealand white rabbits with collagenase-induced knee osteoarthritis, randomised to: saline control, hyaluronic acid (HA) alone, AOD-9604 alone (0.25 mg intra-articular), or combined AOD-9604 + HA. Both AOD-9604 and HA groups showed significantly better cartilage scores than saline control. The combined AOD-9604 + HA group showed significantly better outcomes than either compound alone. Lameness duration was shorter in the combined group than any other. The authors concluded intra-articular AOD-9604 enhanced cartilage regeneration, with a synergistic effect when combined with HA.

Important caveat: this is a single animal model study. No Phase III cartilage trials have been conducted. No human clinical evidence for AOD-9604 in osteoarthritis exists as of 2026. The cartilage research direction is early-stage and hypothesis-generating.

Sophie, a rheumatology researcher at a London university hospital, had been following the synovial biology literature since the Kwon et al. 2015 paper appeared. She was specifically interested in whether beta-adrenergic receptor modulation in synovial tissue could influence the inflammatory cascade in osteoarthritic joints. She wasn’t drawing clinical conclusions from one rabbit study. She was building the mechanistic rationale for a cell culture protocol to test whether the chondroprotective signal was real. That’s how early-stage research works – one credible animal study generates the hypothesis that justified the next step.

Research Applications

Adipose Tissue Biology and Fat Metabolism

The primary and best-evidenced research application: studying the mechanisms by which the beta-3 adrenergic pathway drives lipolysis in adipose tissue. Research protocols using AOD-9604 as a tool compound allow investigators to stimulate fat breakdown and inhibit fat synthesis without the IGF-1 and glucose confounds that full hGH introduces. Particularly valuable for:

  • Beta-3 adrenergic receptor pharmacology in adipocytes
  • Hormone-sensitive lipase activation and triglyceride hydrolysis mechanisms
  • The relationship between lipolysis and lipogenesis pathways as a coupled system
  • Adipocyte signalling in obese versus lean animal models
  • Fat oxidation kinetics measured by indirect calorimetry

Metabolic Syndrome and Obesity Models

AOD-9604 has been used as a probe compound in research examining the molecular underpinnings of obesity and metabolic syndrome. Its selectivity for fat metabolism pathways without endocrine side effects makes it a useful comparator in studies that also examine GLP-1 receptor agonists, leptin signalling, or other metabolic interventions. The well-characterised clinical safety database (900+ trial participants) gives researchers confidence about the compound’s tolerability profile – a level of human data that most research peptides do not have.

Cartilage and Joint Biology

Following the Kwon et al. (2015) study, AOD-9604 has attracted interest from researchers examining joint health and osteoarthritis models. Research protocols in this area typically use cell culture systems with chondrocytes exposed to inflammatory stimuli (IL-1b, TNF-alpha) to examine whether AOD-9604 modulates inflammatory markers, ECM component synthesis (type II collagen, aggrecan), and cartilage degradation enzymes (MMP-13, ADAMTS-5). The mechanistic rationale for why a lipolytic peptide would affect cartilage is not fully established. This area warrants further mechanistic investigation before clinical conclusions can be drawn.

Storage Requirements for Research Settings

AOD-9604 storage follows the same principles as other lyophilized research peptides. The compound is sensitive to moisture, heat, and repeated freeze-thaw cycles.

Storage State Condition Duration
Lyophilized (sealed, unopened) -20°C or below, protected from light and moisture 24+ months under optimal conditions
Lyophilized (working stock) 2-8°C, away from light Short-term acceptable; return to -20°C for long-term storage
Reconstituted in bacteriostatic water 2-8°C immediately after reconstitution Up to 28 days
Reconstituted in sterile water 2-8°C 24-48 hours only. No preservative – single-use preparation
Reconstituted, frozen -20°C in single-use aliquots Extends stability; avoid freeze-thaw cycling on aliquots

Pre-Reconstitution Checks

  • Confirm the CAS number (221231-10-3) on the vial matches the Certificate of Analysis
  • Verify HPLC purity on the COA – research-grade standard is 98%+ purity
  • Confirm mass spectrometry identity verification against the known molecular weight (~1,817 Da)
  • Allow the sealed vial to equilibrate to room temperature before opening – prevents condensation inside the vial
  • The lyophilized powder should appear white to off-white. Any discolouration should be investigated against the COA before reconstitution

Reconstitute in bacteriostatic water (BAC water, 0.9% benzyl alcohol) for multi-draw research protocols. Inject the BAC water slowly down the inside wall of the vial – not directly onto the lyophilized powder. Swirl gently to dissolve; do not shake. The reconstituted solution should be completely clear and colourless.

Tom had been working with a UK supplier for six months and kept receiving AOD-9604 batches where the lyophilized powder had clumped significantly – a sign of moisture exposure during storage or shipping. He contacted Pure Grade Labs, requested the batch-specific COA before placing an order, and specifically asked about cold-chain shipping. The COA showed 99.2% HPLC purity and confirmed mass spectrometry identity. The batch arrived in proper cold packaging. The powder was fine, white, and reconstituted cleanly. The difference between a usable research batch and a degraded one often comes down to supplier storage and shipping discipline – not just the compound itself.

UK Legal Status

  • Not listed under the Misuse of Drugs Act 1971 – possession is not a criminal offence
  • Does not hold MHRA Marketing Authorisation – cannot be legally sold for human therapeutic use in the UK
  • Legal to purchase as a research chemical for laboratory use from suppliers operating within the genuine research-only framework
  • Banned by WADA under the S0 category (non-approved substances) – relevant for competitive athletes in regulated sports

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a synthetic 16-amino acid peptide derived from amino acids 176-191 of human growth hormone, with a stabilising tyrosine modification at the N-terminus. It was developed as a potential anti-obesity drug by Metabolic Pharmaceuticals in Australia, designed to replicate hGH’s fat-metabolising properties without activating the growth hormone receptor or raising IGF-1. Development was discontinued in 2007 after Phase IIb trials failed to demonstrate sufficient efficacy. It remains available as a research chemical for laboratory use.

What is the CAS number for AOD-9604?

The CAS number for AOD-9604 is 221231-10-3. This is the unique chemical identifier to verify against the Certificate of Analysis when sourcing the compound for research. The molecular formula is C78H123N23O23S2 and the approximate molecular weight is 1,817 Da.

Is AOD-9604 the same as HGH Fragment 176-191?

Related but not identical. HGH Fragment 176-191 refers to the natural sequence of amino acids 176 to 191 at the C-terminal end of human growth hormone – 15 amino acids. AOD-9604 is a modified version with a tyrosine residue added at the N-terminus, making it 16 amino acids. The tyrosine modification was engineered to enhance stability and activity. AOD-9604 is the version that underwent formal clinical development; HGH Fragment 176-191 has no published human trial data.

Why did AOD-9604 fail as a drug?

The Phase IIb trials failed to demonstrate statistically significant weight loss at the primary endpoint across the full dose range tested. The 12-week trial showed a modest signal at the 1 mg dose (mean 2.6 kg loss vs 0.8 kg placebo), but this did not hold at higher doses or replicate in the longer 24-week trial. The safety data was excellent – no IGF-1 elevation, no glucose impairment, no immunogenicity – but a drug needs both safety and efficacy for approval. The efficacy case was not established at scale.

Is AOD-9604 legal to buy in the UK?

Yes, for laboratory research purposes. AOD-9604 is not a controlled substance under the Misuse of Drugs Act 1971. It can be purchased legally in the UK as a research chemical from suppliers operating within the research-only framework – proper labelling with no medicinal claims, and batch-specific Certificates of Analysis from independent third-party laboratories. It cannot be legally sold for human therapeutic use. Banned under WADA S0 for competitive athletes.

AOD-9604 from Pure Grade Labs

Batch-specific COA. HPLC purity verified. Mass spectrometry identity confirmed. CAS 221231-10-3. UK research chemical supplier.

Get Pure Grade Peptides →

Summary

AOD-9604 (CAS: 221231-10-3) occupies a distinctive position in the research peptide landscape: it is one of the few compounds in this category to have generated a substantial human clinical safety database (six trials, 900+ participants), and one of the few where the preclinical evidence was strong but human efficacy failed to follow at commercial scale.

Its mechanism – beta-3 adrenergic receptor-driven lipolysis and ACC inhibition reducing lipogenesis – is well-characterised and mechanistically confirmed via genetic knockout models. The Stier et al. (2013) pooled safety analysis establishes that it does not raise IGF-1, does not impair glucose, and produced no immunogenicity signal across six controlled trials. These are the relevant assurances for a research context.

The compound’s primary research utility is as a tool for studying fat metabolism pathways in isolation from the broader endocrine effects of full hGH. Its emerging cartilage research direction following Kwon et al. (2015) is early-stage and hypothesis-generating. For UK researchers sourcing AOD-9604, the key verification requirements are: CAS 221231-10-3 on the COA, HPLC purity at 98%+, and mass spectrometry identity confirmation against the known molecular weight of approximately 1,817 Da.

References

  1. Heffernan MA et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12):5182-5189. PMID: 11713213
  2. Heffernan MA et al. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment AOD9604. Obesity Research, 9(5):341-347. PMID: 11673763
  3. Heffernan MA et al. (2000). Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism in rodents and in human adipose tissue. American Journal of Physiology – Endocrinology and Metabolism, 279(3):E501-507. PMID: 10950816
  4. Stier H, Vos E, Kenley D. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, 3(1-2):7-15. PMID: 23761285
  5. Kwon DR, Park GY, Lee SC. (2015). Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science, 45(4):426-432
Disclaimer: This article is for research and informational purposes only. AOD-9604 has not received MHRA Marketing Authorisation and is not approved for human therapeutic use in the UK. All Pure Grade Labs products are sold as research chemicals for laboratory use only and are not intended for human consumption. This content does not constitute medical advice.